All IndicationsOncologyPhase 3Phase 3Phase 3Phase 3Phase 3Phase 1
🎗️
relapsed/refractory multiple myeloma
8
Companies
11
Drug Programs
5
Phase 3
0
Upcoming PDUFAs
Competitors
CBDY
Celgene
Teclistamab
BMY
Bristol Myers Squibb
iberdomide
ABBV
AbbVie
etentamig
ABBV
AbbVie
Etentamig
JNJ
Johnson & Johnson
TECVAYLI
CBDY
CellBody Therapeutics
Cevostamab
PFE
Pfizer
elranatamab
TRAX
Traxis Pharmaceuticals
CAR T-Cell Therapy
ACTI
Arcus Therapeutics
CAR T-Cell Therapy
LEGN
Legend Biotech
Carvykti
JNJ
Johnson & Johnson
ciltacabtagene autoleucel
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| CBDY Celgene | Teclistamab | Phase 3 | — | — | — |
| BMY Bristol Myers Squibb | iberdomide | Phase 3 | — | — | — |
| ABBV AbbVie | etentamig | Phase 3 | — | — | — |
| ABBV AbbVie | Etentamig | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | TECVAYLI | Phase 3 | — | — | — |
| CBDY CellBody Therapeutics | Cevostamab | Phase 1 | — | — | — |
| PFE Pfizer | elranatamab | — | — | — | — |
| TRAX Traxis Pharmaceuticals | CAR T-Cell Therapy | — | — | — | — |
| ACTI Arcus Therapeutics | CAR T-Cell Therapy | — | — | — | — |
| LEGN Legend Biotech | Carvykti | — | — | — | — |
| JNJ Johnson & Johnson | ciltacabtagene autoleucel | — | — | — | — |
Development Stage Distribution
Unknown
5
Phase 3
5
Phase 1
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.